Sisram Medical Ltd (HKG:1696)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 894.54M -65.4% |
| Revenue (ttm) | 2.91B +7.4% |
| Net Income | 89.67M -44.5% |
| EPS | 0.19 -44.4% |
| Shares Out | 468.34M |
| PE Ratio | 9.98 |
| Forward PE | 3.31 |
| Dividend | 0.10 (4.97%) |
| Ex-Dividend Date | Aug 26, 2026 |
| Volume | 118,000 |
| Open | 1.955 |
| Previous Close | 1.995 |
| Day's Range | 1.910 - 1.990 |
| 52-Week Range | 1.875 - 5.780 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 4.41 (+130.89%) |
| Est. Earnings | Nov 19, 2026 |
About Sisram Medical
Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, trans-epidermal delivery, face and body contouring, cellulite treatment... [Read more]
Financial Performance
In 2025, Sisram Medical's revenue was $365.35 million, an increase of 4.65% compared to the previous year's $349.11 million. Earnings were $19.02 million, a decrease of -24.32%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for 1696 stock is "Strong Buy." The 12-month stock price target is $4.41, which is an increase of 130.89% from the latest price.
News
Sisram Medical Earnings Call Transcript: H1 2026
Revenue grew 3.6% year-over-year to $171.4 million, led by APAC and injectables, though profitability was impacted by strategic investments and North America softness. APAC now leads regional growth, injectables surged 54.2%, and new product launches and localization in China are set to drive H2 momentum.
Sisram Medical Earnings release: H1 2026
Sisram Medical released its H1 2026 earnings on August 20, 2026, summarizing the period's financial results.
Sisram Medical Slides: H1 2026
Sisram Medical has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 20, 2026.
Sisram Medical Quarterly report: H1 2026
Sisram Medical has published its H1 2026 quarterly earnings report on August 20, 2026.
Sisram Medical Delivers Solid 2026 Interim Results
Injectables Business Fuels Rapid Growth as APAC Drives International Revenue Expansion HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with it...
Sisram Medical Bolsters EBD and Injectables in Thailand to Unlock APAC Growth
With advancing EBD rollout and steady injectables expansion, integrated treatment protocols deliver unique competitive edges for high-quality regional growth HONG KONG, June 22, 2026 /PRNewswire/ -- S...
Sisram Medical Investor Day Key Takeaways
Advancing Global Medical Aesthetics Strategy and Unl ock ing Wellness Platform Value HONG KONG, May 27, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness ...
Sisram Medical Earnings Call Transcript: H2 2025
Revenue grew 4.7% to $365.3M in 2025, led by APAC and injectables, while North America declined 19.2% amid macro headwinds. Gross margin fell to 58.9% due to tariffs and mix, but adjusted net profit rose 7.9%. Strategic focus remains on ecosystem integration, AI, and new product launches.
Sisram Medical Earnings release: H2 2025
Sisram Medical released its H2 2025 earnings on March 24, 2026, summarizing the period's financial results.
Sisram Medical Slides: H2 2025
Sisram Medical has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
Sisram Medical Annual report: H2 2025
Sisram Medical has published its H2 2025 annual report on March 24, 2026.
Sisram Medical Reports Solid Growth in 2025
Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidly DAXXIFY shows promising results from initial commercialization in China, with exp...
Sisram Medical to Announce 2025 Annual Results on Monday, March 23, 2026
Earnings Conference Call to be Held on March 24, 2026 HONG KONG, March 12, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively refe...
Alma, a Sisram Medical Company, Advances the Future of Intelligent Aesthetics at IMCAS World Congress 2026
New clinical evidence highlights a smarter, technology-driven approach to scar management, rejuvenation, and tattoo removal HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or...
Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China
HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offeri...
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; tog...
Sisram Medical Launches Universkin by Alma in Hong Kong, Pioneering a New Era of AI-assisted Personalized Skincare
HONG KONG , Nov. 21, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness gr...
Sisram Medical Delivers Strong Third-Quarter 2025 Performance with Robust Momentum Across Key Markets and Core Businesses
HONG KONG , Oct. 28, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness gr...